Vivanza Biosciences Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 515837, "name": "Vivanza Biosci.", "stock_name": "Vivanza Biosci.", "full_name": "Vivanza Biosciences Ltd", "name_url": "stocks-analysis/vivanza-biosci", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "1.70", "chg": "0.00", "chgp": "0.00%", "dir": 0, "prev_price": "1.70", "mcapval": "7.00 Cr", "mcap": "Micro Cap", "scripcode": 530057, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 67, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE984E01035", "curr_date": "Jun 15, 03:30 PM", "curr_time": "09:19 AM", "last_traded_at": "Jun 15, 03:30 PM IST", "bse_nse_vol": "25.71 k", "exc_status": "Active", "traded_date": "Jun 15, 2026", "traded_date_str": "2026 06 15", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Vivanza Biosciences Gains 3.45% Despite Downgrade and 52-Week Low", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-gains-345-despite-downgrade-and-52-week-low-4052483", "imagepath": "", "date": "2026-06-13 17:31:24", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Downgrade to Strong Sell by MarketsMOJO</p>\n <p><strong>3 June:</strong> Stock hits 52-week low of Rs.1.65</p>\n <p><strong>5 June:</strong> Week closes at Rs.1.80, up 3.45% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.74</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.80</div><div class=\"stat-change positive\">+3.45%</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week High</div..." }, { "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.52 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-falls-to-52-week-low-amidst-continued-market-pressure-4044124", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivanzaBioscien_priceRelatedfactors_4044124.png", "date": "2026-06-10 10:37:32", "description": "A sharp decline of 13.14% in a single session has dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.52 on 10 Jun 2026, marking a significant underperformance against its sector and the broader market." }, { "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.65 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-falls-to-52-week-low-amidst-continued-downtrend-4033748", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivanzaBioscien_priceRelatedfactors_4033748.png", "date": "2026-06-03 10:36:24", "description": "A sharp decline of 8.84% today dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.65, extending its downward trajectory despite recent positive quarterly results. This drop comes amid broader market weakness, with the Sensex also falling sharply, but the stock’s underperformance remains pronounced." }, { "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-technical-and-fundamental-concerns-4030156", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivanzaBioscien_mojoScore_4030156.png", "date": "2026-06-02 08:46:08", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This adjustment reflects deteriorating technical indicators, persistent operating losses, and underwhelming long-term financial trends despite recent positive quarterly results." }, { "title": "Vivanza Biosciences Declines 1.69% Amid Mixed Technical Signals and Financial Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-declines-169-amid-mixed-technical-signals-and-financial-challenges-4023469", "imagepath": "", "date": "2026-05-30 17:06:31", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>25 May:</strong> Stock opens steady at Rs.1.77 with no price change</p>\n <p><strong>26 May:</strong> Rating upgraded to Sell by MarketsMOJO on technical improvements</p>\n <p><strong>27 May:</strong> Stock dips 1.13% to Rs.1.75 amid mixed market signals</p>\n <p><strong>29 May:</strong> New 52-week low of Rs.1.74 recorded, closing the week down 1.69%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.77</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div..." }, { "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.74 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-falls-to-52-week-low-of-rs174-amidst-continued-downtrend-4020113", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_priceRelatedfactors_4020113.png", "date": "2026-05-29 10:41:33", "description": "A sustained decline has pushed Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.74 on 29 May 2026, marking a 28.4% drop over the past year and signalling continued pressure on this micro-cap pharmaceutical stock despite some recent positive financial results." }, { "title": "Vivanza Biosciences Ltd Upgraded to Sell on Technical Improvements Despite Long-Term Challenges", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-on-technical-improvements-despite-long-term-challenges-4012939", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_mojoScore_4012939.png", "date": "2026-05-26 08:34:57", "description": "Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators amid persistent fundamental weaknesses. While the company’s financial trend shows some positive quarterly results, its long-term fundamentals and valuation metrics continue to weigh on investor sentiment, resulting in a cautious outlook." }, { "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Weakness", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-technical-and-fundamental-weakness-3998309", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_mojoScore_3998309.png", "date": "2026-05-19 08:30:38", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This revision reflects deteriorating technical indicators, persistent operating losses, and weak long-term fundamentals despite recent positive quarterly financial results." }, { "title": "Vivanza Biosciences Falls 5.00%: Valuation Shifts and Q4 Losses Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-500-valuation-shifts-and-q4-losses-shape-the-week-3983601", "imagepath": "", "date": "2026-05-09 17:05:41", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 4:</strong> Week opens at Rs.2.00</p>\n <p><strong>May 6:</strong> Valuation shifts signal changing price attractiveness</p>\n <p><strong>May 8:</strong> Q4 FY26 results reveal sharp loss reversal despite revenue surge</p>\n <p><strong>May 8:</strong> Stock closes week at Rs.1.90 (-5.00%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.00</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.90</div><div class=\"stat-change neg..." } ], "total": 198, "sid": "515837", "stock_news_url": "https://www.marketsmojo.com/news/vivanza-biosciences-515837" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "09-May-2026", "details": "In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region where the registered office of the Company is situated for extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended on March 31st 2026", "source": "BSE" }, { "caption": "Results- Quarterly And Year To End Dated 31St March 2026", "datetime": "07-May-2026", "details": "Audited Standalone Financial Results for the Quarter and Year ended on 31st March 2026 Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS Reconstitution of Committees of the Board", "source": "BSE" }, { "caption": "Non Applicability Of Related Party Transaction Under Regulation 23(9) Of SEBI (LODR) Regulations 2015 For The Quarter And Year Ended 31St March 2026", "datetime": "07-May-2026", "details": "This is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations 2015 Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations 2015 shall not apply to listed entities having paid up equity share capital not exceeding Rupees 10 crores and net worth not exceeding Rupees 25 crores as on the last day of previous financial year. The paid-up equity share capital and net worth of the Company as on 31st March 2025 are Rs. 40000000 and Rs. 40203752.40 respectively", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23", "dt": "2023-03-24", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Downgrade to Strong Sell by MarketsMOJO

3 June: Stock hits 52-week low of Rs.1.65

5 June: Week closes at Rs.1.80, up 3.45% for the week

Week HighRead full news article

Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.52 as Sell-Off Deepens

2026-06-10 10:37:32

A sharp decline of 13.14% in a single session has dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.52 on 10 Jun 2026, marking a significant underperformance against its sector and the broader market.

Read full news article

Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.65 as Sell-Off Deepens

2026-06-03 10:36:24

A sharp decline of 8.84% today dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.65, extending its downward trajectory despite recent positive quarterly results. This drop comes amid broader market weakness, with the Sensex also falling sharply, but the stock’s underperformance remains pronounced.

Read full news article

Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Concerns

2026-06-02 08:46:08

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This adjustment reflects deteriorating technical indicators, persistent operating losses, and underwhelming long-term financial trends despite recent positive quarterly results.

Read full news article

Vivanza Biosciences Declines 1.69% Amid Mixed Technical Signals and Financial Challenges

2026-05-30 17:06:31

Key Events This Week

25 May: Stock opens steady at Rs.1.77 with no price change

26 May: Rating upgraded to Sell by MarketsMOJO on technical improvements

27 May: Stock dips 1.13% to Rs.1.75 amid mixed market signals

29 May: New 52-week low of Rs.1.74 recorded, closing the week down 1.69%

Week Open

Rs.1.77

Week Close

Read full news article

Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.74 as Sell-Off Deepens

2026-05-29 10:41:33

A sustained decline has pushed Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.74 on 29 May 2026, marking a 28.4% drop over the past year and signalling continued pressure on this micro-cap pharmaceutical stock despite some recent positive financial results.

Read full news article

Vivanza Biosciences Ltd Upgraded to Sell on Technical Improvements Despite Long-Term Challenges

2026-05-26 08:34:57

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators amid persistent fundamental weaknesses. While the company’s financial trend shows some positive quarterly results, its long-term fundamentals and valuation metrics continue to weigh on investor sentiment, resulting in a cautious outlook.

Read full news article

Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Weakness

2026-05-19 08:30:38

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This revision reflects deteriorating technical indicators, persistent operating losses, and weak long-term fundamentals despite recent positive quarterly financial results.